Lauxera Capital Partners

The firm was co-founded in 2020 by Pierre Moustial and Alexandre Margoline. Moustial previously spent over a decade in healthcare investment banking at J.P. Morgan in London and Paris, primarily covering medtech and biopharma M&A. Margoline was an investment director at a European single-family office, where he built and managed a concentrated portfolio of private healthcare and technology assets (per public record). Their combined experience in transactional healthcare and principal investing directly shaped Lauxera's thesis of backing regulatory-cleared HealthTech companies at the commercial inflection point.

Lauxera focuses on commercial-stage HealthTech, not pre-revenue or seed-stage startups. The firm typically writes initial equity checks of €15M–€30M as a lead or co-lead investor. Its concentrated portfolio holds 8–12 companies. The mandate requires portfolio companies to have achieved regulatory clearance in at least one major market — CE mark in Europe or FDA clearance in the US — and to have demonstrated early commercial traction before Lauxera commits capital.

The firm's sourcing model combines a European origination network built around clinical key opinion leaders with a transatlantic outbound channel through its San Francisco office. Lauxera's venture partner bench includes practicing surgeons and former FDA regulatory advisors, who surface companies within their clinical subspecialties before those companies engage traditional growth equity processes. This clinical-operator sourcing layer is central to its differentiation from generalist European growth funds.

Lauxera operates as a direct investor and does not allocate to external venture capital or growth equity funds. The firm's structure is a single-fund, deal-by-deal vehicle rather than a fund-of-funds or hybrid platform. Limited partners invest directly into Lauxera's growth fund, which then takes equity positions in individual portfolio companies.

The firm launched its debut fund in 2020 with an anchor commitment from Bpifrance, the French sovereign wealth fund and public investment bank (per the firm's official communications). The fund operates as a closed-end vehicle with a standard 10-year life. Lauxera has not publicly disclosed its full LP base beyond Bpifrance, though the sovereign anchor aligns the firm with a long-duration capital partner that reinforces its regulatory-stage, patient-capital investment horizon.

Lauxera does not invest in biopharma, drug discovery, or pre-clinical therapeutics. The firm also explicitly avoids digital health companies that lack a regulated-medical-device or diagnostic classification pathway — consumer wellness apps and general health SaaS fall outside its mandate. The exclusion of therapeutics and unregulated health software is central to its positioning as a commercial-stage medtech and diagnostics investor rather than a broad life sciences platform.

Lauxera typically leads or co-leads its rounds and has shown a willingness to syndicate with US-based specialist healthcare investors when its portfolio companies enter the American market. The firm's San Francisco office was established partly to facilitate these co-investor relationships. Lauxera has not disclosed a formal co-investment vehicle for its LPs, but it structures some deals to accommodate direct limited-partner co-investment alongside the main fund.